NO20032613L - Farmasöytisk sammensetning som har forbedret vannlöselighet - Google Patents
Farmasöytisk sammensetning som har forbedret vannlöselighetInfo
- Publication number
- NO20032613L NO20032613L NO20032613A NO20032613A NO20032613L NO 20032613 L NO20032613 L NO 20032613L NO 20032613 A NO20032613 A NO 20032613A NO 20032613 A NO20032613 A NO 20032613A NO 20032613 L NO20032613 L NO 20032613L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical composition
- water solubility
- improved water
- improved
- solubility
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000375601 | 2000-12-11 | ||
| PCT/JP2001/010768 WO2002048141A1 (fr) | 2000-12-11 | 2001-12-10 | Composition medicinale dont la solubilite dans l'eau est amelioree |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20032613D0 NO20032613D0 (no) | 2003-06-10 |
| NO20032613L true NO20032613L (no) | 2003-08-05 |
Family
ID=18844590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20032613A NO20032613L (no) | 2000-12-11 | 2003-06-10 | Farmasöytisk sammensetning som har forbedret vannlöselighet |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040058956A1 (fr) |
| EP (1) | EP1350792A1 (fr) |
| KR (1) | KR20040025880A (fr) |
| CN (1) | CN1487935A (fr) |
| AU (1) | AU2002221096A1 (fr) |
| CA (1) | CA2431319A1 (fr) |
| HU (1) | HUP0401811A2 (fr) |
| NO (1) | NO20032613L (fr) |
| PL (1) | PL362979A1 (fr) |
| WO (1) | WO2002048141A1 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| WO2003031442A1 (fr) * | 2001-10-05 | 2003-04-17 | Takeda Chemical Industries, Ltd. | Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation |
| KR100717098B1 (ko) | 2002-02-28 | 2007-05-10 | 니뽄 다바코 산교 가부시키가이샤 | 에스테르 화합물 및 그 의약 용도 |
| MY147403A (en) * | 2003-04-29 | 2012-11-30 | Kowa Co | Composition containing medicine extremely slightly solube in water and method for preparation thereof |
| JP4579825B2 (ja) * | 2003-04-29 | 2010-11-10 | 興和株式会社 | 溶出性に優れた超難水溶性薬物含有組成物及びその製造法 |
| US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
| MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| US8101774B2 (en) * | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
| MX2007004973A (es) * | 2004-10-25 | 2007-06-14 | Japan Tobacco Inc | Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion. |
| MX2007005361A (es) * | 2004-11-05 | 2008-01-11 | Cephalon Inc | Tratamientos para cancer. |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| EP1767194A1 (fr) * | 2005-06-09 | 2007-03-28 | Helm AG | Procédé pour la préparation d'adsorbats de drospirenone |
| EP1902732A4 (fr) * | 2005-06-24 | 2009-07-22 | Takeda Pharmaceutical | Agent prophylactique/thérapeutique contre le cancer à expression de her2 |
| US20090093491A1 (en) * | 2005-09-30 | 2009-04-09 | Wolfgang Jenni | Diazine Azole Derivatives, Their Manufacture and Use as Pharmaceutical |
| KR100767349B1 (ko) * | 2006-08-01 | 2007-10-17 | 삼천당제약주식회사 | 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법 |
| AR065720A1 (es) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| AR072777A1 (es) * | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| CA2735899A1 (fr) * | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Formulations liquides de bendamustine |
| EA020767B1 (ru) * | 2009-01-15 | 2015-01-30 | Сефалон, Инк. | Новые формы свободного основания бендамустина |
| EP2581084A4 (fr) * | 2010-05-31 | 2014-06-25 | Astellas Pharma Inc | Dispersion solide comprenant un composé de triazole |
| JP6370550B2 (ja) | 2010-11-24 | 2018-08-08 | メリンタ・サブシディアリー・コーポレイション | 薬学的組成物 |
| EP2765990B1 (fr) * | 2011-10-14 | 2017-09-06 | Array Biopharma, Inc. | Dispersion solide |
| CN103070828B (zh) * | 2011-10-26 | 2016-01-27 | 山东新时代药业有限公司 | 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法 |
| GB2516561B (en) * | 2013-03-15 | 2016-03-09 | Aerpio Therapeutics Inc | Compositions, formulations and methods for treating ocular diseases |
| CA2943024A1 (fr) * | 2014-03-18 | 2015-09-24 | Takeda Pharmaceutical Company Limited | Dispersion solide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5352617A (en) * | 1976-10-25 | 1978-05-13 | Shin Etsu Chem Co Ltd | Solid drug coating composition |
| IT1183574B (it) * | 1985-05-08 | 1987-10-22 | Eurand Spa | Metodo per ottenere una sospensione estemporanea omogenea di microcapsule |
| WO1996019239A1 (fr) * | 1994-12-21 | 1996-06-27 | Yamanouchi Pharmaceutical Co., Ltd. | Composition solide a solubilite et absorbabilite ameliorees |
| PT2177517E (pt) * | 1996-07-24 | 2011-11-10 | Celgene Corp | 2-(2,6-dioxopiperidin-3-il)-ftalimida amino-substituída para redução dos níveis de tnf-alfa |
| US6274634B1 (en) * | 1997-05-14 | 2001-08-14 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations with excellent redispersibility |
-
2001
- 2001-12-10 EP EP01270217A patent/EP1350792A1/fr not_active Withdrawn
- 2001-12-10 AU AU2002221096A patent/AU2002221096A1/en not_active Abandoned
- 2001-12-10 HU HU0401811A patent/HUP0401811A2/hu unknown
- 2001-12-10 PL PL01362979A patent/PL362979A1/xx not_active Application Discontinuation
- 2001-12-10 CN CNA018224024A patent/CN1487935A/zh active Pending
- 2001-12-10 WO PCT/JP2001/010768 patent/WO2002048141A1/fr not_active Application Discontinuation
- 2001-12-10 US US10/433,507 patent/US20040058956A1/en not_active Abandoned
- 2001-12-10 KR KR10-2003-7007740A patent/KR20040025880A/ko not_active Application Discontinuation
- 2001-12-10 CA CA002431319A patent/CA2431319A1/fr not_active Abandoned
-
2003
- 2003-06-10 NO NO20032613A patent/NO20032613L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0401811A2 (hu) | 2004-12-28 |
| CN1487935A (zh) | 2004-04-07 |
| WO2002048141A1 (fr) | 2002-06-20 |
| CA2431319A1 (fr) | 2002-06-20 |
| AU2002221096A1 (en) | 2002-06-24 |
| EP1350792A1 (fr) | 2003-10-08 |
| US20040058956A1 (en) | 2004-03-25 |
| KR20040025880A (ko) | 2004-03-26 |
| PL362979A1 (en) | 2004-11-02 |
| NO20032613D0 (no) | 2003-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20032613L (no) | Farmasöytisk sammensetning som har forbedret vannlöselighet | |
| ITTO20000779A0 (it) | Composizioni farmaceutiche. | |
| AR028204A1 (es) | Composiciones farmaceuticas electrohiladas | |
| NO20030153D0 (no) | Blandinger som inneholder terapeutisk aktive komponenter som har foröket löselighet | |
| ITMI20010748A0 (it) | Composizioni farmaceutiche | |
| DE50104135D1 (de) | Wässrige zusammensetzungen | |
| NO20026195D0 (no) | Substituerte-triazolopyrimidiner som anticancer midler | |
| ATE303787T1 (de) | Schergelzusammensetzungen | |
| DK1592457T3 (da) | Folat-vinblastin-konjugat som lægemiddel | |
| ITTO20010005A0 (it) | Formulazione farmaceutica. | |
| DK1524266T3 (da) | Farmaceutisk sammensætning | |
| NO20026175L (no) | Vaksinesammensetning | |
| AR028197A1 (es) | Composiciones antitranspirantes | |
| MXPA03001425A (es) | Compuestos farmaceuticos. | |
| IS7051A (is) | Lyfjasamsetningar | |
| NO20026123L (no) | Farmasöytiske sammensetninger | |
| ATE369830T1 (de) | Schweisshemmende zusammensetzungen | |
| ATE314049T1 (de) | Schweisshemmende zusammensetzungen | |
| NO20032614L (no) | Farmasöytisk sammensetning som har forbedret absorberbarhet | |
| NO20040860L (no) | Farmasoytisk sammensetning som innbefatter lumiracoxib | |
| NO20031095L (no) | Farmasoytiske sammensetninger | |
| NO20013441D0 (no) | Sammensetninger som har forbedret stabilitet | |
| ATE266316T1 (de) | Fungizide zusammensetzungen | |
| DK1263734T3 (da) | 3-thiomethylpyrazoler som pesticider | |
| IT250181Y1 (it) | Custodia perfezionata per rivoltella |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |